Aspen Neuroscience: ARCH Venture Fund XIV buys 1.2M shares
The preferred-stock conversions occurred automatically upon the IPO closing and required no further consideration.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Aspen Neuroscience, Inc. reported common-stock purchases on November 2, 2026: ARCH Venture Fund X, L.P. purchased 66,666 shares, ARCH Venture Fund X Overage, L.P. purchased 66,667 shares, and ARCH Venture Fund XIV, L.P. purchased 1,200,000 shares, each at $15.00 per share. No Rule 10b5-1 plan is reported. Series Seed, A-1, A-2, B and C preferred stock automatically converted into common stock at a 1-for-9.8821 basis upon the IPO closing, without further consideration.
Insider Trade Summary
Net Buyer: 1,333,333 shares
Net Buy
21 txns
Insider
ARCH Venture Fund X, L.P., ARCH Venture Fund X Overage, L.P., ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Partners X, LLC, CRANDELL KEITH, Burow Kristina, GILLIS STEVEN, NELSEN ROBERT
Role
10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner
Bought
1,333,333 shs ($20.00M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Conversion | Series Seed Convertible Preferred Stock F3, F1, F2 | 187,182 | -- | -- |
| Conversion | Series A-1 Convertible Preferred Stock F3, F1, F2 | 298,258 | -- | -- |
| Conversion | Series A-1 Convertible Preferred Stock F3, F2, F4 | 298,258 | -- | -- |
| Conversion | Series A-2 Convertible Preferred Stock F3, F1, F2 | 286,304 | -- | -- |
| Conversion | Series A-2 Convertible Preferred Stock F3, F2, F4 | 286,304 | -- | -- |
| Conversion | Series B Convertible Preferred Stock F3, F1, F2 | 295,490 | -- | -- |
| Conversion | Series B Convertible Preferred Stock F3, F2, F4 | 295,490 | -- | -- |
| Conversion | Series C Convertible Preferred Stock F3, F1, F2 | 259,948 | -- | -- |
| Conversion | Series C Convertible Preferred Stock F3, F2, F4 | 214,355 | -- | -- |
| Purchase | Common Stock F1, F2 | 66,666 | $15.00 | $1000K |
| Conversion | Common Stock F3, F1, F2 | 187,182 | -- | -- |
| Conversion | Common Stock F3, F1, F2 | 298,258 | -- | -- |
| Conversion | Common Stock F3, F1, F2 | 286,304 | -- | -- |
| Conversion | Common Stock F3, F1, F2 | 295,490 | -- | -- |
| Conversion | Common Stock F3, F1, F2 | 259,948 | -- | -- |
| Purchase | Common Stock F2, F4 | 66,667 | $15.00 | $1.00M |
| Conversion | Common Stock F3, F2, F4 | 298,258 | -- | -- |
| Conversion | Common Stock F3, F2, F4 | 286,304 | -- | -- |
| Conversion | Common Stock F3, F2, F4 | 295,490 | -- | -- |
| Conversion | Common Stock F3, F2, F4 | 214,355 | -- | -- |
| Purchase | Common Stock F5 | 1,200,000 | $15.00 | $18.00M |
Holdings After Transaction:
Series Seed Convertible Preferred Stock — 0 contracts (Direct);
Series A-1 Convertible Preferred Stock — 0 contracts (Direct);
Series A-2 Convertible Preferred Stock — 0 contracts (Direct);
Series B Convertible Preferred Stock — 0 contracts (Direct);
Series C Convertible Preferred Stock — 0 contracts (Direct);
Common Stock — 1,161,074 shares (Direct);
Common Stock — 1,200,000 shares (Indirect, See Footnote)
Holdings Before and After:
Series Seed Convertible Preferred Stock, 187,182 to 0 contracts (Direct);
Series A-1 Convertible Preferred Stock, 596,516 to 0 contracts (Direct);
Series A-2 Convertible Preferred Stock, 572,608 to 0 contracts (Direct);
Series B Convertible Preferred Stock, 590,980 to 0 contracts (Direct);
Series C Convertible Preferred Stock, 474,303 to 0 contracts (Direct);
Common Stock, 0 to 1,200,000 shares (Indirect, See Footnote)
Other Insiders: 1 other insider reported open-market purchases of this stock in the 30 days up to this filing.
Footnotes (5)
- F1. Securities held by ARCH Venture Fund X, L.P. ("ARCH X"). ARCH Venture Partners X, L.P. ("AVP X LP") is the sole general partner of ARCH X.
- F2. ARCH Venture Partners X, LLC ("AVP X LLC") is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow, Steven Gillis, and Robert Nelsen (collectively, the "AVP X Committee Members") comprise the investment committee of AVP X LLC. AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. Each of AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members disclaims beneficial ownership except to the extent of any pecuniary interest therein.
- F3. Each share of Series Seed Convertible Preferred Stock, Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock, and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted on a 1-for-9.8821 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date.
- F4. Securities held by ARCH Venture Fund X Overage, L.P. ("ARCH X Overage"). ARCH Venture Partners X Overage, L.P. ("AVP X Overage LP") is the sole general partner of ARCH X Overage.
- F5. Shares were purchased by ARCH Venture Fund XIV, L.P. ("ARCH XIV"). The AVP X Investment Committee Members also are members of the investment committee for ARCH XIV.
Key Figures
ARCH Venture Fund X purchase: 66,666 shares
ARCH Venture Fund X Overage purchase: 66,667 shares
ARCH Venture Fund XIV purchase: 1,200,000 shares
+3 more
6 metrics
ARCH Venture Fund X purchase
66,666 shares
November 2, 2026, at $15.00 per share
ARCH Venture Fund X Overage purchase
66,667 shares
November 2, 2026, at $15.00 per share
ARCH Venture Fund XIV purchase
1,200,000 shares
November 2, 2026, at $15.00 per share
Purchase price
$15.00 per share
Reported for the three common-stock purchases
Preferred-stock conversion basis
1-for-9.8821
Automatic conversion into common stock upon IPO closing
ARCH Venture Fund XIV shares held after purchase
1,200,000 shares
After the November 2, 2026 purchase
Key Terms
Convertible Preferred Stock, 1-for-9.8821 basis, pecuniary interest
3 terms
Convertible Preferred Stock financial
"Series Seed Convertible Preferred Stock"
Convertible preferred stock is a special class of company shares that pays priority, usually fixed, payments to holders and can be exchanged later for a set number of common shares. It matters to investors because it combines steady income and added protection with the chance to share in a company’s upside; think of it as a hybrid between a bond that pays regularly and an option to convert into growth-oriented stock, where the conversion rules influence both potential gains and how much common shareholders’ ownership may be reduced.
1-for-9.8821 basis technical
"automatically converted on a 1-for-9.8821 basis"
pecuniary interest technical
"except to the extent of any pecuniary interest therein"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What Aspen Neuroscience (ASPE) stock purchases were reported?
ARCH Venture Fund X, L.P. purchased 66,666 shares, ARCH Venture Fund X Overage, L.P. purchased 66,667 shares, and ARCH Venture Fund XIV, L.P. purchased 1,200,000 shares on November 2, 2026. Each purchase was at $15.00 per share, and no Rule 10b5-1 plan is reported.
How did Aspen Neuroscience (ASPE) preferred stock convert to common stock?
Series Seed, A-1, A-2, B and C preferred stock automatically converted into common stock at a 1-for-9.8821 basis upon the closing of the IPO, without payment of further consideration.
AI-generated analysis. How Rhea-AI works. Not financial advice.
